Practices
The problem
“New staff start work without knowing the terms or what applies at our stage, and leads spend their week explaining basics.”
The cost: lead time spent on basics instead of the work, and avoidable mistakes from new staff.
Regulation orientation
The main rule sets in biotech, in the order most companies meet them.
Lab safety and biosafety
Work with biological agents follows biosafety levels, set by the risk of the agent.
Lab records should be complete and traceable from the start.
Good Laboratory Practice
GLP covers nonclinical safety studies that support a filing.
It sets how studies are set up, run, recorded and reported.
The IND
In the US, an IND must be in effect before a new drug or biologic is tested in people.
It includes study data, the clinical plan and a CMC section.
Good Manufacturing Practice
GMP covers how product is made, tested and released.
Clinical material is also made under GMP, with controls suited to the phase.
Good Clinical Practice
GCP covers how clinical trials are designed, run and reported.
An IRB reviews each study to protect participants.
Electronic records and data integrity
21 CFR Part 11 covers electronic records and signatures in FDA-regulated work.
ALCOA+ sums up what good data looks like.
Marketing applications
An NDA or BLA asks FDA to approve a product for sale in the US.
After approval, changes and safety reports each have their own rules, for example 21 CFR 601.12 or 314.70 for changes and 600.80 or 314.80 for safety reports.
Other regions
This orientation uses US terms.
Other countries have their own agencies and rules, often with close equivalents.
Related
See what applies at your stage, then the work SI 42 drafts for it.